| 000 | 01774 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513233651.0 | ||
| 264 | 0 | _c20010614 | |
| 008 | 200106s 0 0 eng d | ||
| 022 | _a0085-2538 | ||
| 024 | 7 |
_a10.1046/j.1523-1755.2001.0590041484.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCattran, D C | |
| 245 | 0 | 0 |
_aCyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. _h[electronic resource] |
| 260 |
_bKidney international _cApr 2001 |
||
| 300 |
_a1484-90 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCyclosporine _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlomerulonephritis, Membranous _xdrug therapy |
| 650 | 0 | 4 |
_aGlucocorticoids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aProteinuria _xetiology |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 |
_aSteroids _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAppel, G B | |
| 700 | 1 | _aHebert, L A | |
| 700 | 1 | _aHunsicker, L G | |
| 700 | 1 | _aPohl, M A | |
| 700 | 1 | _aHoy, W E | |
| 700 | 1 | _aMaxwell, D R | |
| 700 | 1 | _aKunis, C L | |
| 773 | 0 |
_tKidney international _gvol. 59 _gno. 4 _gp. 1484-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1523-1755.2001.0590041484.x _zAvailable from publisher's website |
| 999 |
_c11196895 _d11196895 |
||